tetano
Editor, Senior Moderator
Sci Prog
. 2025 Jul-Sep;108(3):368504251366362.
doi: 10.1177/00368504251366362. Epub 2025 Aug 10. Which type of vaccine is more beneficial for reducing the risk of deep vein thrombosis, CoronaVac, BNT162b2, or TURKOVAC?
Süleyman Yazıcı[SUP] 1 [/SUP], Osman Fehmi Beyazal[SUP] 1 [/SUP], Hasan Tezcan[SUP] 1 [/SUP]
Affiliations
ObjectiveThe aim of this study is to reveal the relationship between TURKOVAC, CoronaVac, and BNT162b2 and deep vein thrombosis.MethodsBetween 2022 and 2024, a case-control study was planned with 400 patients included (deep vein thrombosis group (n = 200) and control group (n = 200). Patients were divided into four groups according to their vaccine types. Group 1 (n = 54): those who received only CoronaVac, Group 2 (n = 233): those who received only BNT162b2, Group 3 (n = 49): those who received CoronaVac for the first dose, and then BNT162b2, Group 4 (n = 15): those who received BNT162b2 for the first dose and then TURKOVAC. First, the deep vein thrombosis and control groups were compared regarding basic characteristics. Then, patients in the four groups were compared in terms of deep vein thrombosis.ResultsNo difference was found in the frequency of COVID-19 disease in the deep vein thrombosis and control groups. The frequency of vaccination was lower in the deep vein thrombosis group (84%-91.5%). According to the multivariate regression test result, we found that COVID-19 vaccination was protective against deep vein thrombosis (p = 0.003, OR = 0.377 [95% CI, 0.197-0.722]). After being divided into four groups, the rates of deep vein thrombosis were 36 (66.7%), 96 (41.2%), 29 (59.2%), and 7 (46.7%), respectively. The frequency of deep vein thrombosis was significantly lower in Group 2 (p = 0.003). Although no statistically significant difference was found among other groups, the lowest deep vein thrombosis frequency was found in Group 4, Group 3, and Group 1, respectively.ConclusionThe frequency of COVID-19 vaccination was lower in patients with deep vein thrombosis than in those without. Deep vein thrombosis was least common in patients who received only BNT162b2. Although the frequency of deep vein thrombosis was similar in the groups, we found that the lowest rate of deep vein thrombosis was in the group that received TURKOVAC after BNT162b2.
Keywords: BNT162b2; COVID-19; CoronaVac; TURKOVAC; deep vein thrombosis.
. 2025 Jul-Sep;108(3):368504251366362.
doi: 10.1177/00368504251366362. Epub 2025 Aug 10. Which type of vaccine is more beneficial for reducing the risk of deep vein thrombosis, CoronaVac, BNT162b2, or TURKOVAC?
Süleyman Yazıcı[SUP] 1 [/SUP], Osman Fehmi Beyazal[SUP] 1 [/SUP], Hasan Tezcan[SUP] 1 [/SUP]
Affiliations
- PMID: 40785304
- DOI: 10.1177/00368504251366362
ObjectiveThe aim of this study is to reveal the relationship between TURKOVAC, CoronaVac, and BNT162b2 and deep vein thrombosis.MethodsBetween 2022 and 2024, a case-control study was planned with 400 patients included (deep vein thrombosis group (n = 200) and control group (n = 200). Patients were divided into four groups according to their vaccine types. Group 1 (n = 54): those who received only CoronaVac, Group 2 (n = 233): those who received only BNT162b2, Group 3 (n = 49): those who received CoronaVac for the first dose, and then BNT162b2, Group 4 (n = 15): those who received BNT162b2 for the first dose and then TURKOVAC. First, the deep vein thrombosis and control groups were compared regarding basic characteristics. Then, patients in the four groups were compared in terms of deep vein thrombosis.ResultsNo difference was found in the frequency of COVID-19 disease in the deep vein thrombosis and control groups. The frequency of vaccination was lower in the deep vein thrombosis group (84%-91.5%). According to the multivariate regression test result, we found that COVID-19 vaccination was protective against deep vein thrombosis (p = 0.003, OR = 0.377 [95% CI, 0.197-0.722]). After being divided into four groups, the rates of deep vein thrombosis were 36 (66.7%), 96 (41.2%), 29 (59.2%), and 7 (46.7%), respectively. The frequency of deep vein thrombosis was significantly lower in Group 2 (p = 0.003). Although no statistically significant difference was found among other groups, the lowest deep vein thrombosis frequency was found in Group 4, Group 3, and Group 1, respectively.ConclusionThe frequency of COVID-19 vaccination was lower in patients with deep vein thrombosis than in those without. Deep vein thrombosis was least common in patients who received only BNT162b2. Although the frequency of deep vein thrombosis was similar in the groups, we found that the lowest rate of deep vein thrombosis was in the group that received TURKOVAC after BNT162b2.
Keywords: BNT162b2; COVID-19; CoronaVac; TURKOVAC; deep vein thrombosis.